Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension

BACKGROUND: Dupilumab (monoclonal antibody inhibiting IL‐4/IL‐13 signalling) is approved for use in adolescents aged ≥ 12 years with inadequately controlled moderate‐to‐severe atopic dermatitis (AD). Dupilumab significantly improved AD signs/symptoms in a 16‐week, randomised, placebo‐controlled phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Hultsch, T., Davis, J.D., Zhang, Y., Zhu, X., Chen, Z., Li, M., Ardeleanu, M., Teper, A., Akinlade, B., Gadkari, A., Eckert, L., Kamal, M.A., Ruddy, M., Graham, N.M.H., Pirozzi, G., Stahl, N., DiCioccio, A.T., Bansal, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972638/
https://www.ncbi.nlm.nih.gov/pubmed/31595499
http://dx.doi.org/10.1111/bjd.18476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972638/
https://www.ncbi.nlm.nih.gov/pubmed/31595499
http://dx.doi.org/10.1111/bjd.18476

Ejemplares similares